Recruitment

Recruitment Status
Completed
Estimated Enrollment
94

Inclusion Criteria

Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication

Exclusion Criteria

History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

Summary

Conditions
  • Glaucoma
  • Ocular Hypertension
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication

Exclusion Criteria

History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

Locations

Racine, Wisconsin
Racine, Wisconsin

Tracking Information

NCT #
NCT02097719
Collaborators
Not Provided
Investigators
Study Director: Medical Director Allergan